Acrivon Therapeutics, Inc. (ACRV) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform. The company's lead candidate, ACR-368 (prexasertib), is a selective CHK1/CHK2 inhibitor currently in a registrational-intent Phase 2 trial for platinum-resistant ovarian and endometrial cancers. The company also has a preclinical pipeline including ACR-2316, a WEE1/PKMYT1 inhibitor.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(18.8) million | $(35.3) million | $(26.7) million |
| Operating Expenses | $21.4 million | $39.1 million | $29.9 million |
| Research & Development (R&D) | $15.0 million | $26.5 million | $20.3 million |
| General & Administrative (G&A) | $6.4 million | $12.6 million | $9.6 million |
| Cash, Cash Equivalents & Investments | $220.4 million (as of June 30, 2024) | ||
| Accumulated Deficit | $151.7 million (as of June 30, 2024) | ||
| Net Cash Used in Operating Activities | $(31.0) million (YTD 2024) |
Material Changes vs. Prior Period
- Capital Raise: In April 2024, the company closed a Private Investment in Public Equity (PIPE) transaction, raising net proceeds of $123.8 million through the sale of 8.2 million shares of common stock and pre-funded warrants for 7.1 million shares.
- Expense Growth: R&D expenses increased by $6.2 million (31%) year-over-year for the six months ended June 30, 2024. This was driven by a $4.1 million increase in costs related to the ACR-368 clinical trial and a $1.9 million increase in personnel costs.
- Investment Activity: Net cash used in investing activities was $82.2 million for the six months ended June 30, 2024, primarily due to the purchase of short-term and long-term investments ($163.2 million) following the capital raise, partially offset by maturities.
- Interest Income: Interest income increased to $4.1 million for the six months ended June 30, 2024, compared to $3.6 million in the prior year period, reflecting higher cash balances and interest rates.
Guidance, Outlook, and Risks
- Clinical Progress: In April 2024, the company reported positive data from its Phase 2b trial of ACR-368, showing a 50% confirmed objective response rate in OncoSignature-positive patients with platinum-resistant ovarian or endometrial cancer. The company is on track to file an Investigational New Drug (IND) application for ACR-2316 in Q3 2024.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments of $220.4 million are sufficient to fund operations into the second half of 2026.
- Risks: The company has no approved products and has never generated revenue. It expects to continue incurring significant losses. Risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital if needed, and the potential for delays in regulatory approvals.
- Unusual Items: The company recorded $1.8 million in R&D expenses related to milestone payments to Akoya Biosciences for the companion diagnostic agreement during the quarter.
Key Facts for Investor Verification
- Verify the sustainability of the $220.4 million cash runway against the projected burn rate of approximately $31 million per six months in operating cash usage.
- Monitor the enrollment and data readouts for the registrational-intent Phase 2 trial of ACR-368, specifically the validation of the OncoSignature biomarker.
- Track the timeline for the IND filing of ACR-2316, currently targeted for Q3 2024.
- Review the terms of the April 2024 PIPE transaction, including the 7.1 million pre-funded warrants exercisable at $0.001, which are included in the weighted average share count for EPS calculations.
- Assess the impact of the $168 million potential milestone payments owed to Eli Lilly and Company upon the achievement of development and commercial milestones for ACR-368.